Drugs / Conventional itraconazole
Conventional itraconazole
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT03572049 Comparator | Sep 2018 → May 2021 | fungal infectious disease | University of Alabama at Birmingham | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Conventional itraconazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03572049 ↗ |
| Known as | c-itra | “This open-label randomized trial evaluated the efficacy, safety, and pharmacokinetics SUBA-itra compared with conventional itraconazole (c-itra) treatment for endemic fungal infections.” PMID 38440302 ↗ Jan 2024 |
| Known as | C-ITZ | “Super bioavailability (SUBA) itraconazole (S-ITZ), which releases drug in the duodenum, and conventional itraconazole (C-ITZ), which releases drug in the stomach, were compared...” PMID 32457106 ↗ Jul 2020 |